Related Experiment Video
Updated: Jul 13, 2026
08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Published on: October 26, 2017
Biomarkers in cervical cancer screening
Nicolas Wentzensen1, Magnus von Knebel Doeberitz
1Department of Applied Tumor Biology, Institute of Pathology, University of Heidelberg, 69120 Heidelberg, Germany.
Disease Markers
|July 14, 2007
Summary
Pap tests reduce cervical cancer but have limitations. Novel biomarkers could improve screening by identifying high-risk lesions, reducing costs and enhancing early detection of human papillomavirus (HPV) infections.
Area of Science:
- Oncology
- Virology
- Molecular Biology
Background:
- Cytological screening via Pap tests significantly reduced cervical cancer incidence in industrialized nations.
- Limitations include equivocal results requiring costly follow-up, as some high-grade lesions are missed.
- Human papillomavirus (HPV) infection is crucial for cervical cancer development, but most infections clear spontaneously.
Purpose of the Study:
- To review novel biomarkers for cervical cancer screening.
- To focus on biomarkers detecting molecular events indicative of lesion progression.
- To assess the clinical evidence for applying these biomarkers in refined screening programs.
Main Methods:
- Review of scientific literature on cervical cancer biomarkers.
- Analysis of biomarkers targeting molecular events of HPV oncogene expression (E6/E7).
- Evaluation of clinical evidence for biomarker utility in primary screening and triage.
Main Results:
- Persistent HPV infections with deregulated E6/E7 expression are key to cancer progression.
- Novel biomarkers can monitor these molecular events in cytological or histological samples.
- Improved triage of equivocal Pap tests may substantially reduce healthcare costs.
Conclusions:
- Biomarkers targeting molecular events offer improved detection of high-risk cervical lesions.
- These markers hold potential for enhancing both primary cervical cancer screening and triage strategies.
- Further clinical evidence is needed to support the application of novel biomarkers in screening programs.
